Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
复制标题
光化性角化病病变中治疗前原卟啉 IX 浓度可能是对基于氨基乙酰丙酸的光动力疗法反应的预测生物标志物。
DOI：
10.1016/j.pdpdt.2015.10.006
复制
发表时间：
2015
影响因子：
3.3
通讯作者：
Chapman,MS
中科院分区：
文献类型：
--
作者：
Kanick,SC;Davis,SC;Zhao,Y;Sheehan,KL;Hasan,T;Maytin,EV;Pogue,BW;Chapman,MS
尽管氨基乙酰丙酸（ALA）诱导的原卟啉IX（PpIX）光动力疗法（PDT）是FDA批准的治疗光化性角化病（AK）的有效疗法，但相当一部分患者（高达25%）对治疗无反应。本研究检查了使用治疗前测量AK病变中PpIX浓度来预测ALA-PpIX PDT反应的可行性。
Although Aminolevulinic Acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment. This study examined the feasibility of using pre-treatment measurements of PpIX concentration in AK lesions to predict response of ALA-PpIX PDT.